TL
CBAY

TrueWealth LLC’s Cymabay Therapeutics CBAY Stock Holding History

TrueWealth LLC’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-243
Closed -$3K – 828
2018
Q3 		$3K Hold
243
– – ﹤0.01% 705
2018
Q2 		$3K Buy
+243
New +$3.04K ﹤0.01% 710

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

TrueWealth LLC's CBAY Position: Q4 2018 in Review

TrueWealth LLC sold out of Cymabay Therapeutics (CBAY) in Q4 2018, closing a stake of 243 shares — an estimated $3K sold.

TrueWealth LLC first reported a position in CBAY in Q2 2018 and held it in 2 quarters. The position peaked at $3K in Q3 2018. 131 funds tracked by Wall St. Rank hold CBAY as of Q4 2018.

  • TrueWealth LLC reported no remaining Cymabay Therapeutics position as of Q4 2018 after selling out during the quarter.
  • TrueWealth LLC sold 243 Cymabay Therapeutics shares in Q4 2018, an estimated $3K.
  • TrueWealth LLC first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 2 quarters.
  • TrueWealth LLC's Cymabay Therapeutics position peaked at $3K in Q3 2018.
  • 131 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2018.

Based on TrueWealth LLC's 13F filing for Q4 2018, filed 18 Jan 2019.